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in the control of human breast cancer cell line
growth and motility via the FAK pathway
Jun Jia1,2*, Tracey Amanda Martin1*, Lin Ye1 and Wen Guo Jiang1Abstract
Background: Fibroblast Activation Protein alpha (FAP-α) or seprase is an integral membrane serine peptidase.
Previous work has not satisfactorily explained both the suppression and promotion effects that have been observed
in cancer. The purpose of this work was to investigate the role of FAP-α in human breast cancer. Expression of
FAP-α was characterized in primary tumour samples and in cell lines, along with the effects of FAP-α expression
on in vitro growth, invasion, attachment and migration. Furthermore the potential interaction of FAP-α with other
signalling pathways was investigated.
Results: FAP-α was significantly increased in patients with poor outcome and survival. In vitro results showed that
breast cancer cells over expressing FAP-α had increased growth ability and impaired migratory ability. The growth
of MDA-MB-231 cells and the adhesion and invasion ability of both MCF-7 cells and MDA-MB-231 cells were not
dramatically influenced by FAP-α expression. Over-expression of FAP-α resulted in a reduction of phosphorylated
focal adhesion kinase (FAK) level in both cells cultured in normal media and serum-free media. An inhibitor to FAK
restored the reduced motility ability of both MCF-7exp cells and MDA-MB-231exp cells and prevented the change
in phosphorylated FAK levels. However, inhibitors to PI3K, ERK, PLCϒ, NWASP, ARP2/3, and ROCK had no influence this.
Conclusions: FAP-α in significantly associated with poor outcome in patients with breast cancer. In vitro, FAP-α
promotes proliferation and inhibits migration of breast cancer cells, potentially by regulating the FAK pathway. These
results suggest FAP-α could be a target for future therapies.
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Fibroblast Activation Protein alpha (FAP-α) or Seprase is
a member of the serine integral membrane peptidases
(SIMPs) family which also includes prolylendopeptidase,
dipeptidyl peptidase IV (DPPIV or CD26), and dipeptidyl
peptidase IIX. These peptidases are inducible, specific
for proline-containing peptides, and are active on the
cell surface [1,2]. Previous studies have demonstrated
that FAP-α has an important role in development of
cancers by modifying bioactive of substrate peptides and
their cellular functions. However, the tissue distribution
and function of FAP-α remains unclear.* Correspondence: vm26jun@gmail.com; martinta1@cf.ac.uk
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reproduction in any medium, provided the orFAP-α has been shown to be transiently expressed in cer-
tain normal fetal mesenchymal tissues, during wound heal-
ing and in reactive stroma responding to most o sarcomas
and epithelial cancers including breast cancer, oesophageal
cancer, colon cancer, pancreatic adenocarcinoma [3-6].
Normal adult tissues, haematopoietic cells as well as ma-
lignant epithelial cells are generally FAP-α -negative. How-
ever other studies have shown that FAP-α expression is
not confined to stromal fibroblasts but that it is also
expressed in some epithelial malignant cells. Kelly et al.
[7] analyzed paraffin-embedded breast-cancer sections and
revealed the expression of FAP-α in cancer cells. A study
by Okada K et al. [8] showed that FAP-α immunoreactivity
was recognized in both intestinal-type and diffuse type of
gastric cancer accompanied with different levels of protein
expression when detected by immunoblotting. FAP-α
immunoreactivity was observed in some microinvasiveThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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grees of FAP-α -positive stromal cells [9]. Recently, it
has been demonstrated that FAP-α is highly expressed
on the surface of glioma cells, bone and soft tissue tumour
cells [10,11].
There are also contradictive results about the function
of FAP-α, in that it could act as both a tumour suppres-
sor and tumour promoter. It has been observed that the
expression of FAP-α decreased the tumourigenicity of
mouse melanoma cells in animals and restored contact
inhibition and growth factor dependence [12]. FAP-α
has also been shown to suppress growth of NSCLC cells,
accompanied by the increased expression of cell surface
DPPIV [13]. Furthermore, increased stromal expression
of FAP-α is shown to be associated with longer survival
of breast cancer patients [3]. In contrast, it has also been
shown that FAP-α can also act as a tumour promoter.
Anti-sense suppression of FAP-α in human breast cancer
cell lines MDA-MB-435 and MDA-MB-436, which nor-
mally express FAP-α rendered these cells sensitive to
serum starvation, whilst high levels of FAP-α expression
were less dependent on exogenous serum factors for
growth and gained independence from normal growth
regulatory controls [14]. The human breast cancer cell
line MDA-MB-231 expressing FAP-α grew more rapidly
and was produced highly vascular tumours in vivo [15].
Mice inoculated with FAP-transfected HEK293 cells
were two to four times more likely to develop tumours
compared with vector-transfected HEK293 controls,
with a 10- to 40-fold enhancement in tumour growth
[16]. Antibody abrogation of FAP-α enzymatic activity
by site-directed mutagenesis of FAP-α was shown to
result in a significant reduction in FAP-driven tumour
growth in vivo [17].
A recent investigation suggested that FAP-α promoted
tumour growth and invasion of breast cancer cells might
be through non-enzymatic functions. Huang et al. [18]
introduced different inhibitors of prolyl peptidases in-
cluding Val-boroPro (talabostat); Glu-boroPro (PT-630);
or 1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-
pyrrolidine (LAF-237) to investigate the function of FAP-
α on breast cancer cells in a SCID mice model. Their
results showed that PT-630 and LAF-237 did not slow the
growth of tumours produced by any of the three breast
cancer cell lines expressing FAP-α. Talabostat slightly de-
creased the growth rates of the FAP-α -expressing tu-
mours but the growth retardation was likely not related to
the inhibition of FAP-α or the related post-prolyl peptid-
ase dipeptidyl peptidase IV. Breast cancer cells expressing
a catalytically inactive mutant of FAP-α (FAPS624A) also
produced tumours that grew rapidly [18]. In another
study, the over-expression of FAP-α in the human hepatic
stellate cell (HSC) cell line LX-2 increased cell adhesion, mi-
gration and invasion. However the proteolytic activityof FAP-α was not necessary for these functions [19].
These findings imply that in addition to its enzymatic
functions, FAP-α might have important non-enzymatic
functions involved in regulating the development and
spread of cancer cells.
Therefore, in this study we analyzed the function of
FAP-α in breast cancer cells with the intention to ex-
plore the non-enzymatic function of FAP-α. Our hy-
pothesis is that as a membrane protein, FAP-α might
participate in the regulation of other membrane mole-
cules or signaling pathways by which exert its influence
on tumour cells.
Methods
Materials and cell lines
Human breast cancer cells, MCF7 and MDA-MB-231
were from the ATCC (American Type Cell Collection,
Manassas, VA, USA). Fresh frozen human breast tissues
were collected from University Hospital of Wales under
the approval of the local ethical committee, obtained im-
mediately after surgery and stored at −80°C until used.
Antibodies to human FAP-α (sc-100528 and ab5066),
FAK (sc-1680) and pFAK (sc-11765-R were from Santa-
Cruz Biotechnologies, Inc. (Santa Cruz, CA, USA or
Abcam, Cambridge, UK). ROCK inhibitor was from
Santa-Cruz Biotechnologies, Inc. (Santa Cruz, CA, USA),
ERK inhibitor, Wortmannin, and Wiskostatin were from
Calbiochem (Nottingham, UK). Matrigel (reconstituted
basement membrane) was purchased from Collaborative
Research Products (Bedford, MA, USA). Transwell plates
equipped with a porous insert (pore size 8 μm) were from
Becton Dickinson Labware (Oxford, UK). RT-PCR reagents
and plasmid extraction kits were from Sigma (St. Louis,
MO, USA).
Construction of expression vector of human FAP-α and
transfection of breast cancer cells
Touch-down PCR was used to generate the cDNA of
FAP-α from human prostate tissues with primers 5’-
TTAGTCTGACAAAGAGAAACACTG and 5’-ATGAA
GACTTGGGTAAAAATCG. The cDNA of FAP-α was
subsequently cloned into a pEF6/V5-His vector (Invitro-
gen, Paisley, Scotland, UK). The new plasmid, named
pEF6/V5- FAP was amplified in E. coli and verified by
PCR reaction by using a pair of different primers 5’-
AGAGCTTTAGCAATCTGTGC and 5’-TCCCTTGCT
AATTCAAGTGT.
Breast cancer cells MCF7 and MDA-MB-231 were cul-
tured in DMEM media. The cells were transfected with
plasmid pEF6/V5- FAP-α by electroporation. Following
selection of transfected cells with blasticidin (used at
5 μg/ml) and verification by PCR, the stably trans-
fected cells were established: FAP-α over-expression
cells MCF7exp and MDA-MB-231 exp, plasmid only
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wild type cells MCF7wt and MDA-MB-231wt. The
transfected cells thus created were always kept in a
maintenance medium which contained 0.5 μg/ml blas-
ticidin. Pooled populations of genetically manipulated
cells from multiple clones were used in the subsequent
studies.
In vitro cell function including cell growth, adhesion,
invasion, and migration assay
Cell growth assay: cells were plated into 96-well plated
at 2,000 cells/well. Cells were fixed in 10% formaldehyde
on the day of plating, and the day3 and day 5 subse-
quently. 0.5% crystal violet (w/v) was used to stain cells.
Following washing, the stained crystal violet was dis-
solved with 10% (v/v) acetic acid and the absorbance
was determined at a wavelength of 540 nm using an
ELx800 spectrophotometer (Bio-Tek, ELx800). Absorb-
ance represents the cell number.
Adhesion assay: a 96-well plate was pre-coated with
5 μg of Matrigel and allowed to dry overnight. Following
rehydration with serum-free media, 20,000 cells were
seeded into each well. After 40 min of incubation, non-
adherent cells were washed off using BSS buffer. The
remaining cells were fixed with 4% formalin and stained
with 0.5% crystal violet. The number of adherent cells
was then counted under microscopy.
Invasion assay: transwell inserts (upper chamber) with
8 μm pore size were coated with 50 μg of Matrigel (Col-
laborative Research Products, Bedford, Massachusetts,
USA) and air-dried. Following rehydration with serum-
free media, cells were seeded at a density of 30,000 per
insert. After 3 day’s incubation, cells that had migrated
through the matrix and adhered to the other side of
the insert were fixed in 4% formalin, stained with 0.5%
(weight/volume) crystal violet, and counted under a
microscope.
Migration/wounding assay: cells were seeded at a
density of 250,000 per well into a 24-well plate and
allowed to reach confluence by overnight culture. The
monolayer of cells was then scraped with a fine gauge
needle to create a wound of approximately 200 μm.
The movement of cells to close the wound was recorded
for 4 hours. The movement of cells were analyzed by track-
ing cell boundary, for each frame in a series, using the
Optimas 6.0 motion analysis (Meyer Instruments, Houston,
Texas).
Electric Cell-substrate Impedance Sensing (ECIS) based
cell adhesion and motility assay
Electric Cell-substrate Impedance Sensing (ECIS, Applied
Biophysics Inc, Troy, NY, USA) instrument ECIS Zθ
(Theta) was also used to record both cell adhesion and mi-
gration abilities which were shown here as the changes ofresistance. 96W1E arrays were incubated with complete
medium for 1 hour. 50,000 cells of breast cancer cells were
seeded into each well. The electric changes were continu-
ously monitored for up to 24 hr while an electric wounding
was performed after 6 hours. Multiple conditions of fre-
quency 1000 Hz, 2000Hz, 4,000 Hz, and 8,000 Hz were
used to screen the nature of resistance changes.
Influence of inhibitors of signalling pathway on adhesion
and migration of breast cancer cells by ECIS assay
In order to explore the potential crosstalk of FAP-α and
other adhesion and migration associated signalling path-
way. We introduced inhibitors of FAK, ROCK, PLC-γ,
and PI3K pathway in ECIS based cell adhesion and mo-
tility assay. 50,000 cells of breast cancer cells were sus-
pended in 200 ul media with inhibitors of FAK, ROCK,
PLC-γ, and PI3K respectively and the final concentration
was 100 nm. The electric changes were continuously
monitored for up to 24 hr under multiple condition of
frequency while an electric wounding was performed
after 6 hours.
Flow cytometric analysis of in breast cancer cells
In this study, we utilised the Vybrant® Apoptosis Assay Kit
(Invitrogen, Inc., Paisley, UK) to perform the apoptosis
assay. Cells including those suspended in the culture
medium were harvested and washed in cold BSS buffer.
After centrifugation, the cell pellet was resuspended in 1X
annexin-binding buffer. Determine the cell density and di-
lute in 1X annexin-binding buffer to about 1 × 106 cells/ml.
5 μl of FITC annexin V and 1 μl of the PI working solution
(100 μg/ml) were added to each 100 μl of cell suspension
and incubated at room temperature for 5 min. After the in-
cubation, 400 μl of 1X annexin-binding buffer was
added, mixed gently and stored on ice. Cells were ana-
lyzed using the Partec CyFlow® SL flow cytometer and
FlowMax software package (Partec GmbH, Munster,
Germany), measuring the fluorescence emission at 530 nm
and >575 nm.
Immunofluorescence staining in breast cancer cells
20,000 cells were seeded in each well of a 16-well chamber
and cultured overnight. Then cells were fixed in 100%
ethanol for 30 minutes. After blocked in a 10% horse
serum solution, cells were incubated with primary anti-
bodies overnight and were incubated for 30 min in the
secondary FITC- and TRITC conjugated antibodies. Fol-
lowing extensive washings, the slides were mounted using
Fluorsave™ mounting media (Calbiochem, Nottingham,
UK) and allowed to harden overnight in the refrigerator
before being examined. Slides were examined using an
Olympus fluorescence microscope and photographed
using a Hamamatsu digital camera. The images were
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England, UK).
Western blotting and Immunoprecipitation
To detect the expression level of FAP-α in breast cancer
cell lines, confluent cells were pelleted and then lysed
using a lysis buffer containing 2.4 mg/ml Tris, 4.4 mg/
ml NaCl, 5 mg/ml sodium deoxycholate, 20 μg/ml
sodium azide, 1.5% Triton, 100 μg/ml PMSF, 1 μg/ml
leupeptin, and 1 μg/ml aprotinin, for 45 min at 4°C.
After lysis and centrifugation at 13,000 rpm for 15 min,
protein concentrations for each sample were measured
using an improved Lowary assay (DC Protein Assay kit,
Bio-Rad). The samples were adjusted to equal concen-
trations with sample buffer and then boiled at 100°C
for 5 min, before separated on a 10% polyacrylamide
gel. Following electrophoresis, these separated proteins
were transferred onto nitrocellulose sheets and blocked
in 10% skimmed milk (w/v in TBS) for overnight. The
membranes were then probed with the anti-FAP-α, anti-
FAK antibodies, and anti-GAPDH antibody as internal
control, followed by a peroxidase-conjugated secondary
antibody. Protein bands were visualised using an ECL
system (Amersham, UK), and photographed using an
UVITech imager (UVITech, Inc). The proteins obtained
from breast cancer cells were immunoprecipitated with
10 μl of anti-FAP-α and anti-FAK antibodies for 2 h at
4°C followed by the addition of 20 μl of protein A/G-
agarose beads overnight at 4°C. The resultant pellet was
subjected to SDS-PAGE and Western blotting by anti-
bodies against the FAP-α and phosphatised FAK.
Human breast tissues
A total of 133 breast samples were obtained from breast
cancer patients (106 breast cancer tissues and 27 associ-
ated background or related normal tissue). The anon-
ymised breast tissue samples were obtained within the
guidelines of the appropriate ethics committee (Bro Taf
Health Authority 01/4303 and 01/4046). Informed patient
consent was not applicable in this instance (as stated in the
Human Tissue Act 2004, UK). The pathologist verified
normal background and cancer specimens, and it was con-
firmed that the background samples were free from tumour
deposit. These tissues after mastectomy were immediately
frozen in liquid nitrogen.
Real-time quantitative Polymerase Chain Reaction (Q-PCR)
The assay was based on the Amplifluor system. It was
used to detect and quantify transcript copy number of
FAP-α in tumour and background samples. Primers were
designed by Beacon Designer software, which included
complementary sequence to universal Z probe (Intergen,
Inc.). Each reaction contains 1 pmol reverse primer
(which has the Z sequence), 10 pmol of FAM-taggeduniversal Z probe (Intergen, Inc.) and cDNA (equivalent
to 50 ng RNA). Sample cDNA was amplified and quantified
over a large number of shorter cycles using an iCyclerIQ
thermal cycler and detection software (BioRad laboratories,
Hammelhempstead, UK) under the following conditions:
an initial 5 minute 94°C period followed by 60 cycles of
94°C for 10 seconds, 55°C for 15 seconds and 72°C for
20 seconds. Detection of GAPDH copy number within
these samples was later used to allow further standard-
isation and normalisation of the samples.Statistical Analysis
All of the results are expressed as the means ± S.E. Cell
growth, wounding or migration, adhesion, and invasion
formation was analyzed using a Student's t test on log
normalized data or Mann Witney for patient tissues
(where required).Results
Expression of FAP-α in breast tumour is correlated with
patient prognosis and survival
Analysis carried out using Q-PCR (using CK-19 to nor-
malise) revealed that patients with poor outcome had
the highest levels of FAP-α (Figure 1A). Patients who
remained alive and well had significantly lower levels of
FAP-α than those who had died from breast cancer or
those who had poor outcomes in general (normalised
transcript copy number/50 ng RNA was alive and well
0.878 ± 0.533; median value <0.001: died from breast
cancer 6.44 ± 5.27; median value 0.1: all poor outcomes
(recurrence, metastasis, death) 4.11 ± 3.31; median value
0.02, p = 0.0059 and p = 0.0247 respectively). Lower
levels were also evident in those patients who had bone
metastasis (9.1 ± 8.8; median value 0.02, p = 0.052). FAP-
α was also significantly increased in ER positive and ERβ
positive tumours (Figure 1B). When long-term survival
was analysed using Kaplan-Meier survival curves, pa-
tients with high levels of FAP-α transcript had a signifi-
cantly shorter survival than patients with low levels of
FAP-α (p = 0.036); High levels of FAP-α, mean survival
98.222 ± 17 months (64.853-131.591 months, 95% CI)
versus low levels of FAP-α, 137.587 ± 4.84 months
(128.587-147.086 months, 95% CI, cut-offs as previously
determined [20]). This was also seen in patients who had
remained disease free, who had lower levels of FAP-α
(p = 0.024); High levels of FAP-α, mean survival 90.73 ±
16.8717 months (58.447-121.983 months, 95% CI) versus
low levels of FAP-α, 132.313 ± 5.27 months (121.963-
142.642 months, 95% CI). Immunohistochemical staining
showed a corresponding increase in protein levels of FAP-α
in tumour tissues when compared to background tissue
(Figure 1E). The data for the patient cohort is summarised
in Table 1.
Figure 1 (See legend on next page.)
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Figure 1 Analysis of human breast cancer and background tissues. (A) Q-PCR revealed a significant increase in FAP-α expression with poor patient
outcome. (B) Expression was also increased in ER positive and ERβ positive patients. (C) Kaplan-Meier survival curves showing overall survival analysis of
patients expressing FAP-α. (D) Kaplan-Meier survival curves showing disease-free survival analysis of patients with breast cancer. (E) Immunohistochemical
staining of FAP-α in background breast tissues (left) and tumour/associated tissues (right).
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We analysed the expression pattern of FAP-α in MCF7
and MDA-MB-231 breast cancer cell lines. When using
RT-PCR, we found no transcript of FAP-α mRNA in the
breast cancer cell lines (Figure 2A). After transfection
with plasmid pEF6/V5-FAP-α, transcription of FAP-α
mRNA could be amplified and an increased expression
of FAP-α was also detected in MCF7exp and MDA-MB-
231exp cells (Figure 1B). GAPDH was used as a standard
control. Western blotting for the FAP-α protein showed
successful protein expression in both MCF7 and MDA-
MB-231 cells (Figure 1C).Over-expression of FAP-α promotes growth of MCF-7 cells
and has no effect on apoptosis
In the in vitro cell growth assay, it was observed that a
significantly higher rate of growth was achieved in
FAP-α transfected MCF7 cells (Figure 3A), but that
there was little change in MDA-MB-231 breast cancer
cell growth (Figure 3B). In order to ascertain whether
apoptosis in the cells was reduced, we used flow cy-
tometry to analyse the relative expression of Annexin
V. The results showed that the rate of apoptosis in
MCF7wt, MCF7pef, and MCF7exp were 9.03%, 6.61%,
4.63% respectively in serum free medium and those in
cells cultured in normal media were 5.73%, 6.53%, and
7.21%. There was no significant difference between
cells (Figure 3C).Table 1 Patient population data of samples included in the a
Tissue Type
Background (32) Tumour (120)
Tumour Grade
Grade 1 (22) Grade 2 (40)
NPI
NPI 1 (43) NPI 2 (37)
TNM
TNM 1 (22) TNM 2 (37)
Histology
Ductal (94) Lobular (13)
Outcome
Disease free (86) Metastatic diseaseOver-expression of FAP-α impairs human breast cancer
cell migration
Using a matrigel based in vitro invasion assay, it was
found that MCF7exp and MDA-MB-231exp cells had in-
creased invasion ability compared with those of the wild
type and control cells although this did not reach signifi-
cance (MCF7wt, MCF7pef, MCF7exp, MDA-MB-231wt,
MDA-MB-231pef, and MDA-MB-231exp cells were
17.8 ± 17.3, 17.4 ± 15.7, 55.3 ± 34.8, 65.2 ± 36.9, 99.0 ±
72.2, and 112.6 ± 36.8 respectively, P > 0.05) (Figure 4A).
When we examined any effect on cell adhesion to base-
ment membrane, it was seen that MCF7exp cells exhib-
ited lower adhesion but that MDA-MB-231exp cells
were more adhesive compared with those of the wild
type and control cells, although this did not achieve
significance (MCF7wt, MCF7pef, MCF7exp, MDA-MB-
231wt, MDA-MB-231pef, and MDA-MB-231exp cells were
31.3 ± 20.6, 24.3 ± 12.4, 26.7 ± 31.5, 12.7 ± 18.8, 15.5 ± 15.6,
and 14.0 ± 14.4 respectively, P > 0.05) (Figure 4B). This
may be due to the different aggressive behaviour of the
cell lines, as MDA-MB-231 cells are intrinsically more
invasive.
To investigate the impact of FAP-α on migration of cells,
we used the ECIS based wounding assay. This enabled a de-
tailed analysis of the attachment and migration of the cells
in two spate phases. ECIS enables us to firstly measure the
rate of attachment of the cells to the substratum; the faster
the resistance increases, the greater the rate of attachment,
and secondly by enabling us to measure migration of cellsnalyses
Grade 3 (15) Unknown (43)
NPI 3(15) Unknown (5)
TNM 3 (7) TNM 4 (4) Unknown (48)
Other (13)
(6) Local recurrence (5) Death from breast
cancer (16)
All poor outcomes (27)
Figure 2 Expression of FAP-α in human breast cancer cell lines. (A) RT-PCR showing the lack of expression of FAP-α in MCF7 and MDA-MB-231
human breast cancer cell lines. (B) Cells transfected with a FAP-α expression plasmid. GAPDH was used as a control. (C) Western blotting showing
successful expression of FAP-α in both cell lines.
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the addition of a high voltage shock. The reduced resistance
associated with the “wound” is then reversed as cells move
into the cleared area, the resistance plateauing when the
cleared space is filled. In the adhesion phase of ECIS,
MCF7exp cell showed reduced attachment after 2 hours,
whereas MDA-MB-231exp attachment was increased,
compared to control cells (Figure 4B) (p < 0.05, n = 8). The
confluent cell monolayer was then wounded and the ex-
periment resumed to examine changes in migration. In the
migration phase, the results showed that the motility of
both MCF7exp cells and MDA-MB-231exp cells was dra-
matically reduced compared to the wild type and control
cells (P < 0.05) (Figure 4D).
FAK inhibitor could restore the impaired motility ability
of breast cancer cells.
In searching for the potential pathway(s) that may be re-
sponsible for the impact of FAP-α expression on breast
cancer cells, we screened a panel of small molecule in-
hibitors to some of the key signalling pathways that are
linked to cell motility. They included the ROCK inhibi-
tor, JNK inhibitor, PI3K inhibitor, FAK inhibitor and
ERK inhibitor. Using ECIS (n = 16 for each experiment),
we assessed the effect of these inhibitors on cell migra-
tion/motility. Again, we looked at the two phases of the
experiment, attachment and migration. There was little
difference in attachment upon addition of the small in-
hibitors to MCF7exp cells (not shown) but a small dif-
ference with the FAK inhibitor (Figure 5A and B). Only
the FAK inhibitor was seen to partially restore the in-
hibitory effect of FAP-α on the motility of MCF7exp
cells (Figure 5C and D). Again, there was little difference
in after the addition of the inhibitors on MDA-MB-
231exp attachment (Figure 6A and B). The FAK inhibi-
tor was able to partially restore the inhibitory effect of
FAP-α expression in MDA-MB-231 cells (Figure 6Cand D), as in the MCF7 cells. ERK inhibitor had only a
marginal effect on the motility of the control breast
cancer cells however it reversed the inhibition of motility
in MDA-MB-231exp cells to that of the control. This was
more evident at the early phase (within 2 hours after
wounding) (Figure 6D).
Over-expression of FAP-α accompanied with a reduction
of phosphorylated FAK
To investigate the potential crosstalk of FAP-α and the
FAK pathway, we analyzed the proteins expression of
FAP-α and the phosphorylation status of FAK. As shown
in Figure 7A, over-expression of FAP-α in MCF7exp
cells and MDA-MB-231exp cells accompanied a de-
crease in phosphorylated FAK (pFAK) when cultured in
both normal media and serum-free media. Addition of
the FAK inhibitor (FAKi) could restore the levels of FAK
phosphorylation in both MCF7exp cells and MDA-MB-
231exp cells (Figure 7A). Furthermore, we analyzed the
expression of FAK in all genetically modified cells. The
results showed that the over-expression of FAP-α in
MCF7exp and MDA-MB-231exp cells had no influence
on the transcription of FAK compared with those of wild
type and control cells (Figure 7B).
Immunofluorescent staining of FAP-α and FAK in
both MCF7 and MDA-MB-231 cells showed that the
over-expression of FAP-α accompanied a reduction
in the fluorescence intensity of phosphorylated FAK
(Figure 7C, second row). In addition, the inhibitor of
FAK could partially restore the expression of phos-
phorylated FAK (Figure 7C, bottom row). The human
breast cancer cell line BT549 was used as a positive
control for endogenous FAP-α expression.
Discussion
Fibroblast Activation Protein alpha (FAP-α) is an inte-
gral membrane serine peptidase. It has been shown that
Figure 3 Growth of human breast cancer cells overexpressing FAP-α. (A) There was an increase in growth of MCF7exp cells compared to
the controls (n = 8). (B) No equivalent increase was observed in MDA-MB-231 cells. (C) Apoptosis was not reduced in MCF7exp cells.
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gration, invasion and angiogenesis. Recent studies have
provided convincing evidence that targeting FAP-α is a
promising method in both diagnosis and treatment of can-
cer. A combination of FAP-α with other serum markers
such as CEA, CYFRA 21–1, OPN, ferritin, and anti-p53had comparable sensitivity with faecal immunochemical
testing (FIT) for the early detection of colorectal cancer
[21]. Immunotherapy targeting FAP-α could inhibit tumour
growth and increases survival in a murine colon cancer
model. A DNA vaccine directed against FAP-α could
significantly suppressed primary tumour and pulmonary
Figure 4 (See legend on next page.)
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Figure 4 Effect on FAP-α overexpression and cellular behaviour. (A) Increased invasion was observed in both MCF7 and MDA-MB-231 cells
Overexpressing FAP-α (n = 8). (B) Adhesion to basement membrane showed that MCF7exp cells exhibited lower adhesion but that MDA-MB-231exp cells
were more adhesive (n = 8). (C, top) ECIS experiments showed that MCF7exp cell showed reduced attachment after 2 hour, whereas MDA-MB-231exp
attachment was increased (C, bottom). (D) In the migration phase, motility of both MCF7exp cells and MDA-MB-231exp cells was dramatically reduced
compared to the wild type and control cells (n = 16).
Figure 5 Effect of small inhibitors on the impaired motility ability of MCF7 breast cancer cells. A panel of small inhibitors linked to
motility was screened, with only the FAK inhibitor having a substantial effect. ECIS was used to assess the effect of these inhibitors on cell
migration/motility. Again, we looked at the two phases of the experiment, attachment and migration. (A and B) There was little difference in
attachment upon addition of the small inhibitors to MCF7exp cells (n-16). (C and D) The FAK inhibitor was seen to partially restore the inhibitory
effect of FAP-α on the motility of MCF7exp cells (n = 16).
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Figure 6 Effect of small inhibitors on the impaired motility ability of MDA-MB-231 breast cancer cells. (A and B) As for MCF-7 cells,
there was little difference in after the addition of the inhibitors on MDA-MB-231exp attachment (n = 16). (C and D) The FAK inhibitor was
able to partially restore the inhibitory effect of FAP-α expression in MDA-MB-231 cells (n = 16) (D).
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tumour-bearing mice [22]. An antibody-maytansinoid
conjugate, monoclonal antibody (mAb) FAP5-DM1 targeted
at a shared epitope of human, mouse, and cynomolgus
monkey FAP, could induced long-lasting inhibition
of tumour growth and complete regressions in xenograft
models of lung, pancreas, and head and neck cancers with no
signs of intolerability [23]. The clinical impact of FAP-α was
also tested using Val-boroPro (Talabostat), the first clinical in-
hibitor of FAP-α enzymatic activity, in a phase II study of pa-
tients with metastatic colorectal cancer. The results showed
that minimal clinical activity was also observed in patients
with previously treated metastatic colorectal cancer [24]. Our
data has shown that in patients with breast cancer, FAP-α is
significantly over-expressed in those with poor prognosis and
is inversely related to both overall and disease-free survival.
However, until now, there is still no conclusion as to the rela-
tion between FAP-α expression and function.Active FAP-α is a 170 kDa homodimer that contains two
N-glycosylated 97 kDa subunits. The FAP-α monomer has
C-terminal catalytic domains of serine proteases, a hydro-
phobic transmembrane segment and a short cytoplasmic
tail [1,25]. Studies of the mouse homologue have shown
that alternative splicing and 3 distinct FAP-α splice variants
had been detected in tissues [26]. An alternative spliced
FAP-α was later identified in the human melanoma cell line
LOX which encodes a truncated isoform which encodes
a 239 amino acid polypeptide with a molecular weight
of 27 kDa that precisely overlaps the carboxylterminal
catalytic region of the wild type FAP-α [27]. In another
study using a generated soluble recombinant FAP-α, it
was found that in the presence of putative EDTA sensi-
tive activators, FAP-α was converted into 70 kDa to
50 kDa shortened forms [28].
In our study, a 549 bp product of FAP-α could be
amplified in both MCF7exp and MDA-MB-231exp cells
Figure 7 Effect of FAP-α overexpression on FAK phosphorylation. (A) over-expression of FAP-α in MCF7exp cells and MDA-MB-231exp cells
accompanied a decrease in phosphorylated FAK (pFAK) when cultured in both normal media and serum-free media which was restored on
addition of FAKi. (B) over-expression of FAP-α in MCF7exp and MDA-MB-231exp cells had no influence on the transcription of FAK compared with
those of wild type and control cells. (C) Immunofluorescence staining of FAP-α and FAK in both MCF7 and MDA-MB-231 cells showed that the
over-expression of FAP-α accompanied a reduction in the fluorescence intensity of phosphorylated FAK which was partially restored using FAKi.
The human breast cancer cell line BT549 was used as a positive control for endogenous FAP-α expression.
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http://www.biomedcentral.com/1471-2121/15/16while the western-blotting assay of FAP-α protein ex-
pression in breast cancer cells showed that a 30 kDa
truncate was detected instead of the 97 kDa monomer
and 170 kDa dimer. We presumed that it might be
caused by the degradation of FAP-α protein or the use
of antibodies that recognize, with varying affinity, differ-
ent epitopes exhibited by FAP-α.
Some studies have suggested that FAP-α is expressed by
stromal cells rather than cancer cells in epithelial malignant
diseases; however other studies have demonstrated that
FAP-α is also expressed in epithelial malignant cells such as
breast cancer, gastric carcinoma, and cervical carcinoma
[7,8]. In our study, we analyzed the expression of FAP-α by
PCR reaction and western-blot assay. The results showed
that there was no amplification of FAP-α mRNA in both
MCF7 and MDA-MB-231 wild type cells but a weakexpression of FAP-α protein were detected in these cells by
immunoblotting. Moreover, FAP-α was detected in BT-549
breast cancer cells. We tentatively suggest that the negative
result in the earlier studies might be due to the comparative
difference in staining intensity between the high expres-
sions in stromal cells compared to the weaker expression of
FAP-α in cancer cells.
Over-expression of FAP-α in fibroblasts and paracytes of
cancer cells promotes tumour growth, invasion and metas-
tasis by directly remodelling extracellular matrix and target-
ing fibroblast activation protein could inhibit tumour
stromagenesis and growth. Furthermore, some clinical data
has implied that patients with over-expression of FAP-α
identified from stroma had a significantly poorer outcome
[4,29]. Again, there are also contradictive results regarding
the function of FAP-α in that it could act as both a tumour
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overexpression of FAP-α could promote the growth of
MCF7 cells, while no significant difference in proliferation
was observed in MDA-MB-231exp cells compared with
wild type and control cells. A previous study by Huang
et al. [15] also d that MDA-MB-231 cells genetically ex-
pressing FAP-α grew at the same rate as control cells with-
out the expression of FAP-α in vitro. However, when using
a mouse model in vivo, MDA-MB-231 cells expressing
FAP-α grew more rapidly and were highly vascular com-
pared to control cells in vivo [15]. These results indicated
that FAP-α could act as a tumour promoter and this
tumour promotion effect was more noticeable in vivo.
The process of metastasis and invasion of tumour cells
requires these cells to alter their ability to adhere or de-
tach to both stromal cells and the extracellular matrix
(ECM). Membrane Integrins play a crucial role in many
aspects of tumour initiation and progression [30,31].
Focal adhesion kinase (FAK), an intracellular tyrosine
kinase recruited to the sites of integrin clustering or
focal adhesions, functions as a major mediator of signal
transduction by cell surface receptors including integ-
rins, growth factor and cytokine receptors progression
[31-33]. FAK has been shown to play a key role in the
regulation of cell adhesion, migration, and invasion
[33-35]. Our study discovered that over-expression of
FAP-α resulted in decreasing adhesion and migration
ability of MCF7 and MDA-MB-231 cells. However, an
inhibitor of FAK could restore the reduced motility
ability of both MCF-7exp cells and MDA-MB-231exp
cells, while inhibitors to PI3K, ERK and ROCK had no
influence on it. Furthermore, using an immunoprecipi-
tation assay and protein samples extracted from cells cul-
tured in normal media and serum-free media, we found
that the over-expression of FAP-α was associated with a de-
crease in phosphorylated FAK protein under both normal
culture and serum-free culture condition. Moreover, an in-
hibitor to FAK could eliminate this difference in phosphor-
ylated FAK in all the MCF-7 and MDA-MB-231 cell lines.
This implies that FAP-α might form a complex with the
FAK protein and so reduce its phosphorylation, which thus
results in reduction of adhesion and motility ability. Earlier
work had shown that cells expressing FAP-α exhibited a de-
crease in FAK phosphorylation in a murine model [36]. It
has been previously shown that depletion of FAP-α-
expressing stromal cells can impair the growth of immuno-
genic tumours via a lymphocyte dependent mechanism and
that inhibition of FAP-α using extracellular competitive in-
hibitors of dipeptidyl peptidases have been shown to con-
tribute to impaired epithelial cancer growth via a FAP-α
dependant mechanism [36-39]. Little is known about intra-
cellular post-proline cleaving enzymes such as FAP-α in the
context of tumour behaviour and growth compared to
other extracellular proteases [40].Conclusions
In conclusion, we report that FAP-α expression in pa-
tients with breast cancer is increased with poor progno-
sis and patient survival. In vitro data shows that this
increased expression leads to decreased adhesion and
migration of human breast cancer cells. Moreover, this
was associated with increased growth. This effect ap-
peared to be integrated with the phosphorylation status
of FAK, which could be part of the control pathway by
which FAP-α effects change in cancer cells. Further work
is necessary to dissect the pathway in which FAP-α is
involved.
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